PMC:7029759 / 17189-17330
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 372 | 40-44 | Gene | denotes | ACE2 | Gene:59272 |
LitCovid-PMC-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T401 | 40-44 | G_3;PG_10;PR:000003622 | denotes | ACE2 |
| T400 | 135-140 | CHEBI:52217;CHEBI:52217 | denotes | agent |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T89 | 45-52 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T61 | 45-52 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T108 | 0-141 | Sentence | denotes | The key advantage here is that the host ACE2 protein will not change, so there is no concern about escape from binding the therapeutic agent. |